Synergistic effect of “methyl cellulose-dextran” on oral curcumin delivery via casein nanomicelle: fabrication, characterization, and cancer therapeutic efficacy assessment

A casein-methyl cellulose nanocomplex, loaded with curcumin and coated with dextran (DX-CasCur-MC), is designed to enhance curcumin’s oral delivery and inhibit cancer growth. Its physicochemical properties reveal chemical bonding between protein and polysaccharides, transforming curcumin from crysta...

Full description

Saved in:
Bibliographic Details
Published in:Cellulose (London) 2024-11, Vol.31 (16), p.9731-9755
Main Authors: Aboushoushah, Samia F., Abaza, Sana F., Elbialy, Nihal S., Mohamed, Noha
Format: Article
Language:English
Subjects:
Bioorganic Chemistry
Cancer
Casein
Cell death
Cellulose
Ceramics
Chemical bonds
Chemistry
Chemistry and Materials Science
Composites
Conjugation
Dextrans
Effectiveness
Glass
In vivo methods and tests
Natural Materials
Organic Chemistry
Original Research
Physical Chemistry
Polymer Sciences
Polysaccharides
Sustainable Development
Sustained release
Synergistic effect
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A casein-methyl cellulose nanocomplex, loaded with curcumin and coated with dextran (DX-CasCur-MC), is designed to enhance curcumin’s oral delivery and inhibit cancer growth. Its physicochemical properties reveal chemical bonding between protein and polysaccharides, transforming curcumin from crystalline into amorphous state to improve water solubility. The encapsulation efficiency of curcumin reaches 92%, and its release profile in physiological and tumor microenvironments exhibits controlled and sustained release. In vitro studies confirm the significant therapeutic efficacy of DX-CasCur-MC in inducing cancer cell death and DNA damage compared to free curcumin. The effectiveness of DX-CasCur-MC for oral drug delivery is validated in simulated gastrointestinal fluids, with 23 and 69% release in gastric and intestinal fluids, respectively. In vivo studies demonstrate a significant reduction in tumor volume in mice treated with DX-CasCur-MC compared to those treated with free curcumin or untreated, confirming DX-CasCur-MC’s ability to improve curcumin’s pharmacological properties and inhibit tumor growth via repeated oral administration. The conjugation of the two polysaccharides with the hydrocolloidal casein nanomicelles improves the nanocomplexes stability, making DX-CasCur-MC a promising natural candidate for oral curcumin delivery with a significant cancer therapeutic efficacy.
ISSN:0969-0239
1572-882X
DOI:10.1007/s10570-024-06169-0